{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07068542\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"SETHY","nct_id":"NCT07068542","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sethy-nct07068542. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Unresectable, locally advanced or metastatic advanced anaplastic thyroid carcinoma thyroid carcinoma (ATC)","label":"cohort A","type":"EXPERIMENTAL"},{"description":"Unresectable, locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC)","label":"cohort B","type":"EXPERIMENTAL"},{"description":"Unresectable, locally advanced or metastatic advanced poorly differentiated thyroid carcinoma (PDTC)","label":"cohort C","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Advanced Thyroid Carcinoma","Radioiodine-refractory Differentiated Thyroid Cancer","Poorly Differentiated Thyroid Carcinoma"],"enrollment":{"count":94,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab Tirumotecan (SKB264) plus Tislelizumab","otherNames":[],"type":"DRUG"},{"name":"Sacituzumab Tirumotecan (SKB264)","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-01","lead_sponsor":"Zhejiang Provincial People's Hospital","official_title":"A Multicenter, Multi-Cohort, Phase II Study of Sacituzumab Tirumotecan With or Without Tislelizumab in Patients With Advanced Thyroid Cancer","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS) - ATC Cohort","timeFrame":"From first dose until death from any cause (up to approximately 24 months after enrollment)"},{"measure":"Progression-Free Survival (PFS) - PDTC and RAIR-DTC Cohorts","timeFrame":"From first dose until documented disease progression or death (up to approximately 24 months)"}],"references":[],"start_date":{"date":"2025-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer","url":"https://clinicaltrials.gov/study/NCT07068542"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sethy-nct07068542"}